Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Zolbetuximab is a genetically engineered, highly purified chimeric (mouse/human IgG1) monoclonal antibody directed against the tight junction molecule CLDN18.2.”
“The estimated mean clearance (CL) and t 1/2 of VYLOY was 0.0150 L/h and 43.6 d, respectively.”
“Zolbetuximab is not a cytokine modulator and there are no known effects of its mechanism of action on cytochrome P450 or drug transporters; therefore, no in vitro or in vivo drug-drug interaction or transporter studies have been conducted.”
Working under the parallel aged-care framework? Aged-care equivalent →